How should I interpret a thyroid function panel with TSH values of 0.61, 1.73, 1.39 and 0.02 mIU/L (reference 0.40‑3.50) and free T4 13.2 pmol/L (reference 9.0‑19.0) and free T3 4.9 pmol/L (reference 2.6‑6.0)?

Interpretation of Thyroid Function Test Results

Critical Finding: Overt Hyperthyroidism

Your most recent test shows overt hyperthyroidism with a severely suppressed TSH of 0.02 mIU/L (below the reference range of 0.40-3.50) alongside normal free T4 (13.2 pmol/L) and free T3 (4.9 pmol/L), which requires immediate evaluation and likely treatment. 1

Understanding the TSH Trend

Your TSH values show a concerning progression over time:

• Earlier values: 0.61,1.73, and 1.39 mIU/L (all within normal range)
• Most recent value: 0.02 mIU/L (severely suppressed, well below 0.40 mIU/L)

This dramatic drop from borderline-low normal to severely suppressed TSH indicates progression from possible subclinical hyperthyroidism to overt biochemical hyperthyroidism. 1

Why This Pattern Matters

TSH <0.1 mIU/L with normal thyroid hormones indicates subclinical hyperthyroidism, but your TSH of 0.02 mIU/L is even more suppressed, suggesting either early overt hyperthyroidism or T3 toxicosis that requires free T3 measurement. 1, 2

Key Clinical Implications:

• Cardiovascular risk: TSH <0.1 mIU/L carries a 3-fold increased risk of atrial fibrillation over 10 years, particularly in patients over 60 years. 1, 3

• Bone health: Untreated hyperthyroidism accelerates bone mineral density loss, especially in postmenopausal women. 3, 4

• Progression risk: The declining TSH trend suggests autonomous thyroid function (toxic nodule or multinodular goiter) rather than transient thyroiditis. 3, 5

Immediate Next Steps Required

1. Confirm the Diagnosis

Repeat TSH with simultaneous free T4 and total T3 (or free T3) within 2-4 weeks to confirm persistent suppression and rule out T3 toxicosis. 1, 2

• Free T3 measurement is critical because some patients have isolated T3 elevation ("T3 toxicosis") with normal free T4, which your current results don't exclude. 2
• A single suppressed TSH can occasionally occur with assay interference, non-thyroidal illness, or medications, though your progressive decline makes this less likely. 6

2. Determine the Etiology

If TSH remains <0.1 mIU/L on repeat testing, proceed immediately with radioactive iodine uptake and thyroid scan to distinguish between Graves disease, toxic multinodular goiter, or autonomous nodule. 3, 4

• Low but detectable TSH (like your 0.02 mIU/L) in ambulatory patients frequently indicates underlying autonomous thyroid nodules or multinodular goiter. 5
• Physical examination should assess for thyroid nodules, goiter, or Graves' ophthalmopathy. 3

3. Treatment Considerations

Treatment is strongly recommended for TSH <0.1 mIU/L, particularly if you are over 60 years old, have cardiac disease, osteopenia/osteoporosis, or symptoms of hyperthyroidism (palpitations, tremor, weight loss, heat intolerance). 1, 3

Symptomatic Management:

• Beta-blockers (atenolol 25-50 mg daily or propranolol) provide immediate relief for tachycardia, tremor, and anxiety while awaiting definitive diagnosis and treatment. 1
• Dose should target heart rate <90 bpm if blood pressure allows. 1

Definitive Treatment Options (based on etiology):

• Methimazole is first-line for Graves disease (except first trimester pregnancy). 1
• Radioactive iodine ablation for toxic multinodular goiter or autonomous nodules. 3, 4
• Surgery may be considered for large nodules or goiters. 3

Common Pitfalls to Avoid

• Do not assume this will resolve spontaneously – the progressive TSH decline suggests autonomous thyroid function requiring intervention. 3

• Do not wait until TSH normalizes or symptoms develop – cardiovascular and bone complications can occur even in subclinical hyperthyroidism. 1, 3

• Do not rely solely on TSH for monitoring – free T4 and T3 levels guide treatment intensity, as TSH may remain suppressed for months even after achieving euthyroidism. 1

• Avoid iodinated contrast studies until hyperthyroidism is controlled, as iodine exposure can precipitate thyroid storm in patients with autonomous nodules. 4

Monitoring Strategy

If treatment is initiated, monitor free T4 or free T3 every 2-4 weeks initially, targeting high-normal range with the lowest effective medication dose, not TSH normalization. 1

• TSH may remain suppressed for months despite achieving euthyroidism, so treatment adjustments should be based on free T4/T3 levels, not TSH. 1

• Once stable, monitoring can be extended to every 3-12 months. 3